ASX:BDXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
BCAL Diagnostics Ltd
$0.067
$0.003 (4.29%)
Day Range
$0.067 – $0.072
52 Week Range
$0.052 – $0.155
Volume
219.35K
Avg Volume (10D)
78.44K
Market Cap
$24.70M
Price Chart
Market Statistics
Open$0.070
Previous Close$0.070
Day High$0.072
Day Low$0.067
52 Week High$0.155
52 Week Low$0.052
Valuation
Market Cap24.70M
Shares Outstanding368.68M
Price to Book9.87
Trading Activity
Volume219.35K
Value Traded15.14K
Bid$0.067 × 35,710
Ask$0.084 × 95,000
Performance
1 Day-4.29%
5 Day-14.10%
13 Week-19.28%
52 Week15.52%
YTD-36.19%
Technical Indicators
RSI (14)41.97
50-Day SMA$0.074
200-Day SMA$0.092
Latest News
Biotechnology
BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring
BCAL Diagnostics launches BREASTEST Monitor—blood test to monitor post-treatment breast cancer recurrence; 91% sensitivity, 95% NPV.
Biotechnology
BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests
BCAL Diagnostics expands access to early cancer blood tests by embedding GP referral forms in major clinical software; launches EarlyDetection telehealth.
Biotechnology
BCAL Diagnostics Accelerates Avantect Rollout via Sonic Healthcare and Healius Partnerships
BCAL Diagnostics speeds Avantect rollout as Sonic Healthcare and Healius expand access to pancreatic/ovarian cancer tests nationwide.
Biotechnology
BCAL Diagnostics on Track for Australian Launch of Aventect Pancreatic and Ovarian Cancer Tests
BCAL Diagnostics (ASX: BDX) is on track to launch the cutting-edge Avantect pancreatic and ovarian cancer tests onto the Australian market in the new year.